In our experiments, despite an irregular change in total MOG-specific CD8+ T cells in MS patients, MOG-specific CD8+ TCM and CD8+ TEM exhibited a decreasing trend at 14 and 28 d post-treatment with teriflunomide, a well-known immunosuppressant agent (30). The gene discussed is CD8A; the disease is myeloid sarcoma.